<DOC>
	<DOCNO>NCT01736215</DOCNO>
	<brief_summary>The purpose observational study evaluate predictor response erythropoietin ( hormone secrete kidney help formation red blood cell bone marrow ) treatment participant cancer ( abnormal tissue grow spread body kill ) relate anemia ( decreased number red blood cell ) , receive chemotherapy ( treatment cancer use drug ) .</brief_summary>
	<brief_title>An Observational Study Predict Response Erythropoietin Treatment Participants With Cancer Related Anemia Receiving Chemotherapy</brief_title>
	<detailed_description>This observational , prospective ( study follow participant forward time ) , multi-center ( study conduct 1 center ) study identify predictive factor effectively predict response erythropoietin treatment cancer relate anemia participant receive chemotherapy . The entire duration study approximately 1 year . Participants primarily evaluate achieve least 1 gram per deciliter ( g per dl ) rise hemoglobin ( substance carry oxygen give blood red color ) level receive erythropoietin treatment base National Comprehensive Cancer Institute ( NCCN ) V3.2009 practice guideline criterion . Response erythropoietin treatment also predict use independent hematological ( related blood ) factor like C-reactive protein ( CRP - acute serum protein release liver ) . It associate low hemoglobin [ substance carry oxygen give blood red color ] erythropoietin [ hormone secrete kidney help formation red blood cell bone marrow ] resistance ) , erythropoietin ( EPO ) , hemoglobin , hematocrit ( amount red blood cell blood ) , reticulocyte ( immature red blood cell ) count , ferritin ( protein store iron allows body use iron ) , serum iron ( iron blood bound transferrin ) transfer iron binding capacity ( TIBC ) , level . Number blood transfusion participant ' safety monitor throughout study .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Participants nonhematologic malignancy ( cancer progressively enlarge spread tumor , usually fatal successfully treat ) Participants life expectancy least 6 month base Investigator 's clinical judgment Participants receive chemotherapy Participants indication plan receive erythropoietin ( dosage regimen comply Thai FDA approval package insert ) Participants give consent form Participants anemia due factor ( i.e. , iron , B12 folate deficiency , hemolysis [ breakdown red blood cell ] , gastrointestinal bleeding , active bleeding ) Participants previous history erythropoietin treatment Participants receive blood transfusion within 1 month start erythropoietin therapy Pregnant breastfeed female participant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Anemia - cancer relate</keyword>
	<keyword>Eprex ( Erythropoietin alfa )</keyword>
</DOC>